Insider Selling: CRISPR Therapeutics (NASDAQ:CRSP) CEO Sells 10,349 Shares of Stock

CRISPR Therapeutics AG (NASDAQ:CRSP) CEO Samarth Kulkarni sold 10,349 shares of the firm’s stock in a transaction that occurred on Monday, March 16th. The shares were sold at an average price of $48.26, for a total value of $499,442.74. Following the completion of the transaction, the chief executive officer owned 245,834 shares of the company’s stock, valued at approximately $11,863,948.84. This represents a 4.04% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Samarth Kulkarni also recently made the following trade(s):

• On Wednesday, March 11th, Samarth Kulkarni sold 9,798 shares of CRISPR Therapeutics stock. The stock was sold at an average price of $52.80, for a total value of $517,334.40.
• On Thursday, February 19th, Samarth Kulkarni sold 6,967 shares of CRISPR Therapeutics stock. The stock was sold at an average price of $52.58, for a total value of $366,324.86.
• On Tuesday, January 20th, Samarth Kulkarni sold 30,000 shares of CRISPR Therapeutics stock. The shares were sold at an average price of $51.75, for a total value of $1,552,500.00.
• On Thursday, January 22nd, Samarth Kulkarni sold 60,000 shares of CRISPR Therapeutics stock. The shares were sold at an average price of $60.23, for a total transaction of $3,613,800.00.

CRISPR Therapeutics Stock Performance

CRSP traded up $1.67 during trading on Tuesday, reaching $50.09. 1,870,722 shares of the stock were exchanged, compared to its average volume of 1,999,385. The stock has a market cap of $4.81 billion, a P/E ratio of -7.68 and a beta of 1.71. CRISPR Therapeutics AG has a twelve month low of $30.04 and a twelve month high of $78.48. The stock’s 50 day moving average price is $53.96 and its two-hundred day moving average price is $57.25.

CRISPR Therapeutics (NASDAQ:CRSP) last announced its quarterly earnings results on Thursday, February 12th. The company reported ($1.37) EPS for the quarter, missing analysts’ consensus estimates of ($1.15) by ($0.22). CRISPR Therapeutics had a negative net margin of 16,569.77% and a negative return on equity of 26.31%. The firm had revenue of $0.86 million during the quarter, compared to analyst estimates of $4.72 million. During the same quarter in the prior year, the business earned ($1.01) EPS. The business’s revenue was down 97.8% compared to the same quarter last year. Equities research analysts predict that CRISPR Therapeutics AG will post -5.16 earnings per share for the current fiscal year.

Institutional Trading of CRISPR Therapeutics

Institutional investors have recently bought and sold shares of the business. Mcguire Capital Advisors Inc. acquired a new position in shares of CRISPR Therapeutics during the 4th quarter worth approximately $25,000. Ramirez Asset Management Inc. bought a new stake in shares of CRISPR Therapeutics in the fourth quarter valued at approximately $26,000. Rothschild Investment LLC boosted its stake in shares of CRISPR Therapeutics by 836.7% in the fourth quarter. Rothschild Investment LLC now owns 562 shares of the company’s stock valued at $29,000 after buying an additional 502 shares during the period. Thurston Springer Miller Herd & Titak Inc. grew its position in CRISPR Therapeutics by 196.9% during the fourth quarter. Thurston Springer Miller Herd & Titak Inc. now owns 576 shares of the company’s stock worth $30,000 after buying an additional 382 shares in the last quarter. Finally, Thompson Investment Management Inc. acquired a new stake in CRISPR Therapeutics during the third quarter worth approximately $33,000. Institutional investors own 69.20% of the company’s stock.

Analyst Ratings Changes

CRSP has been the subject of a number of research analyst reports. Piper Sandler reiterated an “overweight” rating and set a $110.00 price target (up from $105.00) on shares of CRISPR Therapeutics in a report on Tuesday. Chardan Capital upped their price objective on CRISPR Therapeutics from $74.00 to $76.00 and gave the company a “buy” rating in a research note on Saturday, February 14th. Citizens Jmp cut their price objective on CRISPR Therapeutics from $86.00 to $80.00 and set a “market outperform” rating for the company in a research report on Friday, January 30th. TD Cowen lifted their target price on CRISPR Therapeutics from $40.00 to $45.00 and gave the stock a “hold” rating in a research note on Friday, February 13th. Finally, Citigroup reissued a “buy” rating on shares of CRISPR Therapeutics in a report on Monday, February 16th. Ten research analysts have rated the stock with a Buy rating, six have given a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat, CRISPR Therapeutics presently has an average rating of “Hold” and a consensus price target of $64.53.

About CRISPR Therapeutics

CRISPR Therapeutics AG is a biopharmaceutical company specializing in the development of gene-editing therapies based on the CRISPR/Cas9 platform. The company applies its proprietary technology to modify genes in human cells, aiming to create durable treatments for a range of serious diseases. Its research and development efforts focus on both ex vivo and in vivo applications, enabling targeted correction or disruption of disease-causing genes.

Among its lead programs is CTX001, an ex vivo edited cell therapy designed to treat sickle cell disease and transfusion-dependent β-thalassemia in collaboration with Vertex Pharmaceuticals.